Test drug toripalimab with chemo and radiation for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial studies whether adding toripalimab to radiation plus chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. It also looks at tumor markers (like PD-L1) using stored tumor tissue or a new biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18–65 years old, and you’re male or a non-pregnant female
- Your cancer has been diagnosed as non-keratinizing nasopharyngeal carcinoma (WHO type II or III)
- Your cancer is stage IVa with T4 and/or N3 and you haven’t had prior radiation or chemotherapy for it
- You must be able to provide tumor tissue (stored sample allowed or a new biopsy) for PD-L1 testing
- Your blood, liver, and kidney test results are within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.